Table 2. Clinicopathological factors and TOP2A amplified.

			TOP2A amplified
factor		total	yes	%	no	%	p value
		643	61	9.5	582	90.5
age	50≥	14	17	12.1	124	87.9	0.24
	50<	502	44	8.8	458	90.2
T	*0	2	0	0	2	100	0.044
	1	366	28	7.7	338	92.3
	2	211	22	10.4	189	89.6
	3	36	4	11.1	32	88.9
	4	28	7	25	21	75
N	0	422	37	8.8	385	91.2	0.052
	1	172	15	8.7	157	91.3
	2	35	8	22.9	27	77.1
	3	14	1	7.1	13	92.9
Stage	1	302	27	8.9	275	91.1	0.073
	2	262	21	8	241	92
	3	79	13	16.5	66	83.5
nuclear grade	1	291	12	4.1	279	95.9	<0.001
	2	161	19	11.8	142	88.2
	3	263.6	30	15.7	161	84.3
ER	positive	498	41	8.2	457	91.8	0.044
	negative	145	20	13.8	125	86.2
PgR	positive	434	39	9	395	91	0.48
	negative	209	22	10.5	187	89.5
HER2	positive	134	57	42.2	78	57.8	<0.001
	negative	509	4	0.8	504	99.2
Ki 67	14%>	211	13	6.2	198	93.8	0.044
	≧14%	432	48	10.9	384	89.1
subtype	luminal A	108	0	0	108	100	<0.001
	luminal B	315	1	0.3	314	99.7
	HER2	135	57	42.2	78	57.8
	TNBC	85	3	3.5	82	96.5
TOP2A overexpression	yes	359	48	13.3	311	86.7	<0.001
	no	284	13	4.6	271	95.4
Adjuvant chemotherapy	yes	309	48	15.5	261	84.5	<0.001
	no	334	13	3.9	321	96.1
Adjuvant radiation therapy	yes	413	41	9.9	372	90.1	0.61
	no	230	20	8.7	210	91.3
recurrence	yes	73	4	5.5	69	94.5	0.21
	no	570	57	10	513	90

p value was evaluated using χ² test, ^*T0 means occult breast cancer.

Abbreviations: ER: estrogen receptor; PgR; progesteron receptor; HER2: human epidermal growth factor receptor 2 TNBC: triple negative breast cancer.